Literature DB >> 18202349

Role of the TGF-beta/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension.

Ari L Zaiman1, Megan Podowski, Satya Medicherla, Kimberley Gordy, Fang Xu, Lijie Zhen, Larissa A Shimoda, Enid Neptune, Linda Higgins, Alison Murphy, Sarvajit Chakravarty, Andrew Protter, Pravin B Sehgal, Hunter C Champion, Rubin M Tuder.   

Abstract

RATIONALE: Pulmonary arterial hypertension is a progressive disease characterized by an elevation in the mean pulmonary artery pressure leading to right heart failure and a significant risk of death. Alterations in two transforming growth factor (TGF) signaling pathways, bone morphogenetic protein receptor II and the TGF-beta receptor I, Alk1, have been implicated in the pathogenesis of pulmonary hypertension (PH). However, the role of TGF-beta family signaling in PH and pulmonary vascular remodeling remains unclear.
OBJECTIVES: To determine whether inhibition of TGF-beta signaling will attenuate and reverse monocrotaline-induced PH (MCT-PH).
METHODS: We have used an orally active small-molecule TGF-beta receptor I inhibitor, SD-208, to determine the functional role of this pathway in MCT-PH.
MEASUREMENTS AND MAIN RESULTS: The development of MCT-PH was associated with increased vascular cell apoptosis, which paralleled TGF-beta signaling as documented by psmad2 expression. Inhibition of TGF-beta signaling with SD-208 significantly attenuated the development of the PH and reduced pulmonary vascular remodeling. These effects were associated with decreased early vascular cell apoptosis, adventitial cell proliferation, and matrix metalloproteinase expression. Inhibition of TGF-beta signaling with SD-208 in established MCT-PH resulted in a small but significant improvement in hemodynamic parameters and medial remodeling.
CONCLUSIONS: These findings provide evidence that increased TGF-beta signaling participates in the pathogenesis of experimental severe PH.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18202349      PMCID: PMC2292828          DOI: 10.1164/rccm.200707-1083OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  53 in total

1.  Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor.

Authors:  K N Cowan; A Heilbut; T Humpl; C Lam; S Ito; M Rabinovitch
Journal:  Nat Med       Date:  2000-06       Impact factor: 53.440

2.  Differential effects of apoptotic versus lysed cells on macrophage production of cytokines: role of proteases.

Authors:  V A Fadok; D L Bratton; L Guthrie; P M Henson
Journal:  J Immunol       Date:  2001-06-01       Impact factor: 5.422

3.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis.

Authors:  Q Yu; I Stamenkovic
Journal:  Genes Dev       Date:  2000-01-15       Impact factor: 11.361

4.  Activation of the TGF-beta/activin-Smad2 pathway during allergic airway inflammation.

Authors:  A Rosendahl; D Checchin; T E Fehniger; P ten Dijke; C H Heldin; P Sideras
Journal:  Am J Respir Cell Mol Biol       Date:  2001-07       Impact factor: 6.914

5.  Transcriptional and translational regulation of inflammatory mediator production by endogenous TGF-beta in macrophages that have ingested apoptotic cells.

Authors:  P P McDonald; V A Fadok; D Bratton; P M Henson
Journal:  J Immunol       Date:  1999-12-01       Impact factor: 5.422

6.  Tenascin-C is induced by mutated BMP type II receptors in familial forms of pulmonary arterial hypertension.

Authors:  Kaori Ihida-Stansbury; David M McKean; Kirk B Lane; James E Loyd; Lisa A Wheeler; Nicholas W Morrell; Peter Lloyd Jones
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-06-16       Impact factor: 5.464

7.  Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension.

Authors:  K B Lane; R D Machado; M W Pauciulo; J R Thomson; J A Phillips; J E Loyd; W C Nichols; R C Trembath
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

Review 8.  Severe pulmonary hypertension after the discovery of the familial primary pulmonary hypertension gene.

Authors:  R M Tuder; M E Yeager; M Geraci; H A Golpon; N F Voelkel
Journal:  Eur Respir J       Date:  2001-06       Impact factor: 16.671

9.  Mechanical strain-induced extracellular matrix production by human vascular smooth muscle cells: role of TGF-beta(1).

Authors:  C J O'Callaghan; B Williams
Journal:  Hypertension       Date:  2000-09       Impact factor: 10.190

10.  BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension.

Authors:  R D Machado; M W Pauciulo; J R Thomson; K B Lane; N V Morgan; L Wheeler; J A Phillips; J Newman; D Williams; N Galiè; A Manes; K McNeil; M Yacoub; G Mikhail; P Rogers; P Corris; M Humbert; D Donnai; G Martensson; L Tranebjaerg; J E Loyd; R C Trembath; W C Nichols
Journal:  Am J Hum Genet       Date:  2000-12-12       Impact factor: 11.025

View more
  55 in total

1.  Transforming growth factor-β inhibition attenuates pulmonary arterial hypertension in rats.

Authors:  Aikaterini J Megalou; Chryssoula Glava; Dimitrios L Oikonomidis; Agapi Vilaeti; Maria G Agelaki; Giannis G Baltogiannis; Apostolos Papalois; Antonios P Vlahos; Theofilos M Kolettis
Journal:  Int J Clin Exp Med       Date:  2010-10-23

2.  Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease.

Authors:  Wanli Ma; Weihong Han; Peter A Greer; Rubin M Tuder; Haroldo A Toque; Kevin K W Wang; R William Caldwell; Yunchao Su
Journal:  J Clin Invest       Date:  2011-10-17       Impact factor: 14.808

Review 3.  Matricellular protein thrombospondin-1 in pulmonary hypertension: multiple pathways to disease.

Authors:  Natasha M Rogers; Kedar Ghimire; Maria J Calzada; Jeffrey S Isenberg
Journal:  Cardiovasc Res       Date:  2017-07-01       Impact factor: 10.787

4.  Schistosomiasis-induced experimental pulmonary hypertension: role of interleukin-13 signaling.

Authors:  Brian B Graham; Margaret M Mentink-Kane; Hazim El-Haddad; Shawn Purnell; Li Zhang; Ari Zaiman; Elizabeth F Redente; David W H Riches; Paul M Hassoun; Angela Bandeira; Hunter C Champion; Ghazwan Butrous; Thomas A Wynn; Rubin M Tuder
Journal:  Am J Pathol       Date:  2010-07-29       Impact factor: 4.307

Review 5.  Schistosomiasis and the pulmonary vasculature (2013 Grover Conference series).

Authors:  Brian B Graham; Rahul Kumar
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

Review 6.  Molecular switches under TGFβ signalling during progression from cardiac hypertrophy to heart failure.

Authors:  J Heger; R Schulz; G Euler
Journal:  Br J Pharmacol       Date:  2015-11-16       Impact factor: 8.739

7.  Transforming growth factor-beta1 protects against pulmonary artery endothelial cell apoptosis via ALK5.

Authors:  Qing Lu
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-05-02       Impact factor: 5.464

8.  Therapeutic potential of adipose stem cell-derived conditioned medium against pulmonary hypertension and lung fibrosis.

Authors:  Anandharajan Rathinasabapathy; Erin Bruce; Andrew Espejo; Alana Horowitz; Dhivya R Sudhan; Anand Nair; Dominic Guzzo; Joseph Francis; Mohan K Raizada; Vinayak Shenoy; Michael J Katovich
Journal:  Br J Pharmacol       Date:  2016-08-26       Impact factor: 8.739

9.  Transforming growth factor-beta1 causes pulmonary microvascular endothelial cell apoptosis via ALK5.

Authors:  Qing Lu; Bhuvic Patel; Elizabeth O Harrington; Sharon Rounds
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-03-06       Impact factor: 5.464

10.  VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats.

Authors:  Laszlo Farkas; Daniela Farkas; Kjetil Ask; Antje Möller; Jack Gauldie; Peter Margetts; Mark Inman; Martin Kolb
Journal:  J Clin Invest       Date:  2009-04-20       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.